Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
83 hedge funds and large institutions have $239M invested in Avadel Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
67% more capital invested
Capital invested by funds: $143M → $239M (+$96.3M)
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
12% more call options, than puts
Call options by funds: $13.7M | Put options by funds: $12.3M
9% more funds holding
Funds holding: 76 → 83 (+7)
1% more ownership
Funds ownership: 53.16% → 54.15% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$8.47M |
| 2 |
TLP
Tri Locum Partners
New York
|
+$4.8M |
| 3 |
Millennium Management
New York
|
+$4.27M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$3.62M |
| 5 |
GJL
Gendell Jeffrey L
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$7.32M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$2.07M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.28M |
| 4 |
Two Sigma Investments
New York
|
-$743K |
| 5 |
Renaissance Technologies
New York
|
-$723K |
AVDL Hedge Fund Activity: Q4 2022 in Review
83 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2022, worth a combined $239M — up 67% from $143M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVDL positions and 7 closed out — a net gain of 9 holders — while 25 added to existing stakes and 22 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $8.47M. The largest seller was Brandes Investment Partners, cutting an estimated $7.32M.
- 83 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2022, up from 76 in Q3 2022.
- Funds reported $239M of Avadel Pharmaceuticals stock for Q4 2022, up 67% quarter-over-quarter.
- 16 funds opened new Avadel Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +9 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2022 was Janus Henderson Group, an estimated $8.47M added.
- The largest Avadel Pharmaceuticals seller in Q4 2022 was Brandes Investment Partners, an estimated $7.32M sold.
Based on aggregated 13F filings for Q4 2022.